Join our Free Newsletter and unlock 50% off AltIndexFree newsletter + 50% offJoin free
$7.7M 49.1%
Total revenue, Q2 '26 (USD).

Did Intellia Therapeutics Beat Earnings?

Intellia Therapeutics (NTLA) reported Q2 '26 revenue of $7.7M, down 46.2% year-over-year.

AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Intellia Therapeutics’s job postings, web traffic, and employee business outlook. See the full NTLA stock analysis or the earnings calendar for upcoming reports.

Intellia Therapeutics Quarterly Financial Trends (USD)

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Revenue9.1M13M17M14M14M23M15M7.7M
Gross margin-1,098.3%-807.9%100.0%-465.3%-472.8%73.9%85.4%100.0%
Operating margin-1,589.0%-1,059.9%-726.6%-772.2%-808.9%-428.9%-668.1%-1,472.3%
Net income-136M-129M-114M-101M-101M-96M-96M-107M
Net margin-1,489.5%-1,001.2%-687.6%-710.8%-735.2%-416.2%-639.5%-1,392.3%
EPS————————

Intellia Therapeutics Earnings Trend Analysis

Over the eight quarters from Q3 '24 to Q2 '26, Intellia Therapeutics’s quarterly revenue moved from $9.1M to $7.7M. Net margin expanded from -1489.5% to -1392.3%, against a 100% gross margin in the most recent quarter — a read on whether revenue growth is translating into profit.

When Is Intellia Therapeutics’s Next Earnings Date?

Intellia Therapeutics reports earnings on a quarterly schedule. Its most recent report covered Q2 '26. For the confirmed upcoming date — and every other company reporting soon — see the NTLA earnings calendar.

Frequently Asked Questions: Intellia Therapeutics Earnings

Intellia Therapeutics's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.

Intellia Therapeutics reported Q2 '26 revenue of $7.7M, down 46.2% from the same quarter a year earlier.

Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the NTLA AI Score.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.